HRTX · CIK 818033
What Heron Therapeutics, Inc. told the SEC could break it.
2 self-disclosed vulnerabilities, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
A limited set so far — we surface every cited disclosure we’ve extracted for HRTX. More may follow as additional filings are processed.
In its own words
What could break it.
Sole-source dependency
- Sole-source third-party contract manufacturers and single-supplier critical materialshigh
Heron owns no manufacturing and relies on a small number of third-party manufacturers — some of which are its sole resource for key components of its products — plus critical materials sourced from single suppliers, creating significant supply-disruption risk.
“We currently rely on a small number of third-party manufacturers to produce compounds used in our Products. Certain contract manufacturers are, at the present time (and are expected to be for the foreseeable future), our sole resource to manufacture certain key components of our Products.”
SEC filing →As of 2026
Regulatory & policy
- Proposed U.S. pharmaceutical import tariffs (Section 232; 100% branded-pharma tariff)medium
A Section 232 national-security investigation into pharmaceutical imports and an announced 100% tariff on branded/patented pharmaceuticals from manufacturers without U.S. facilities could raise Heron's costs given its reliance on third-party (potentially offshore) manufacturing.
“the U.S. announced a 100% tariff on any branded or patented pharmaceuticals imported into the U.S., from drug manufacturers that do not have, or are not in the process of building, a manufacturing facility in the U.S., which has been delayed as negotiations with large drug manufacturers continue.”
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch